Product Information
RELISTOR 12 MG/0.6 ML VIAL is a brand product labeled by Salix Pharmaceuticals Inc., priced at $271.5833 per ML under NDC 65649055102. Its NADAC has been published 293 times since Nov 28, 2013.
FDA first approved this application on Apr 24, 2008.
Strength
12 mg/.6mL
Manufacturer
Salix Pharmaceuticals Inc.NDC
65649055102
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/17/2025
Active Ingredients
METHYLNALTREXONE BROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA021964FDA Approved
4/24/2008
On Market Since
4/24/2008
Pharmacological Classes
Price Statistics
The NADAC for RELISTOR 12 MG/0.6 ML VIAL has been published 293 times since Nov 28, 2013, and over the history we have for it it has risen 178.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $271.5833 per ML |
|---|---|
| All-time high | $271.5833 (Oct 1, 2025) |
| All-time low | $97.5858 (Nov 28, 2013) |
| Median price | $159.4361 |
| Average price | $189.8302 |
| Largest weekly change | +44.6% (Dec 21, 2022) |
| Weeks tracked | 293 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+11.1%
5Y
+70.3%
All
+178.3%
Last surveyed Oct 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Salix Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylnaltrexone bromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RELISTOR 12 MG/0.6 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for RELISTOR 12 MG/0.6 ML VIAL, manufactured by Salix Pharmaceuticals Inc., is $271.5833 per ML (NDC 65649055102), effective Oct 1, 2025.
How has the price of RELISTOR 12 MG/0.6 ML VIAL changed over time?
Over the history we have for it, the NADAC for RELISTOR 12 MG/0.6 ML VIAL has risen 178.3%. It has been tracked across 293 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for RELISTOR 12 MG/0.6 ML VIAL?
Since Nov 28, 2013, the NADAC for RELISTOR 12 MG/0.6 ML VIAL has ranged from a low of $97.5858 (Nov 28, 2013) to a high of $271.5833 (Oct 1, 2025), with a median of $159.4361 per ML.
Are there cheaper alternatives to RELISTOR 12 MG/0.6 ML VIAL?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RELISTOR 12 MG/0.6 ML SYRINGE, is $271.2074 per ML — about 0% below RELISTOR 12 MG/0.6 ML VIAL.
Who manufactures RELISTOR 12 MG/0.6 ML VIAL?
RELISTOR 12 MG/0.6 ML VIAL (NDC 65649055102) is labeled by Salix Pharmaceuticals Inc., and CMS classifies it as a brand product.